Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections

Detalhes bibliográficos
Autor(a) principal: Mottola, C
Data de Publicação: 2016
Outros Autores: Matias, C, Mendes, JJ, Melo-Cristino, J, Tavares, L, Cavaco-Silva, P, Oliveira, M
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/2579
Resumo: BACKGROUND: Foot infections are a major cause of morbidity in people with diabetes and the most common cause of diabetes-related hospitalization and lower extremity amputation. Staphylococcus aureus is by far the most frequent species isolated from these infections. In particular, methicillin-resistant S. aureus (MRSA) has emerged as a major clinical and epidemiological problem in hospitals. MRSA strains have the ability to be resistant to most β-lactam antibiotics, but also to a wide range of other antimicrobials, making infections difficult to manage and very costly to treat. To date, there are two fifth-generation cephalosporins generally efficacious against MRSA, ceftaroline and ceftobripole, sharing a similar spectrum. Biofilm formation is one of the most important virulence traits of S. aureus. Biofilm growth plays an important role during infection by providing defence against several antagonistic mechanisms. In this study, we analysed the antimicrobial susceptibility patterns of biofilm-producing S. aureus strains isolated from diabetic foot infections. The antibiotic minimum inhibitory concentration (MIC) was determined for ten antimicrobial compounds, along with the minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC), followed by PCR identification of genetic determinants of biofilm production and antimicrobial resistance. RESULTS: Results demonstrate that very high concentrations of the most used antibiotics in treating diabetic foot infections (DFI) are required to inhibit S. aureus biofilms in vitro, which may explain why monotherapy with these agents frequently fails to eradicate biofilm infections. In fact, biofilms were resistant to antibiotics at concentrations 10-1000 times greater than the ones required to kill free-living or planktonic cells. The only antibiotics able to inhibit biofilm eradication on 50 % of isolates were ceftaroline and gentamicin. CONCLUSIONS: The results suggest that the antibiotic susceptibility patterns cannot be applied to biofilm established infections. Selection of antimicrobial therapy is a critical step in DFI and should aim at overcoming biofilm disease in order to optimize the outcomes of this complex pathology.
id RCAP_4b370968fe0874572e054816d285fd21
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/2579
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot InfectionsHSM MEDAnti-Bacterial Agents/pharmacologyBiofilms/drug effectsBiofilms/growth & developmentCephalosporins/pharmacologyDiabetic Foot/drug therapyDiabetic Foot/microbiologyGentamicins/pharmacologyMethicillin-Resistant Staphylococcus aureus/drug effectsMethicillin-Resistant Staphylococcus aureus/geneticsMethicillin-Resistant Staphylococcus aureus/physiologyMicrobial Sensitivity TestsPolymerase Chain Reaction/methodsStaphylococcal Infections/drug therapyStaphylococcal Infections/microbiologyStaphylococcus aureus/drug effectsStaphylococcus aureus/geneticsStaphylococcus aureus/isolation & purificationStaphylococcus aureus/physiologybeta-Lactams/pharmacologyBACKGROUND: Foot infections are a major cause of morbidity in people with diabetes and the most common cause of diabetes-related hospitalization and lower extremity amputation. Staphylococcus aureus is by far the most frequent species isolated from these infections. In particular, methicillin-resistant S. aureus (MRSA) has emerged as a major clinical and epidemiological problem in hospitals. MRSA strains have the ability to be resistant to most β-lactam antibiotics, but also to a wide range of other antimicrobials, making infections difficult to manage and very costly to treat. To date, there are two fifth-generation cephalosporins generally efficacious against MRSA, ceftaroline and ceftobripole, sharing a similar spectrum. Biofilm formation is one of the most important virulence traits of S. aureus. Biofilm growth plays an important role during infection by providing defence against several antagonistic mechanisms. In this study, we analysed the antimicrobial susceptibility patterns of biofilm-producing S. aureus strains isolated from diabetic foot infections. The antibiotic minimum inhibitory concentration (MIC) was determined for ten antimicrobial compounds, along with the minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC), followed by PCR identification of genetic determinants of biofilm production and antimicrobial resistance. RESULTS: Results demonstrate that very high concentrations of the most used antibiotics in treating diabetic foot infections (DFI) are required to inhibit S. aureus biofilms in vitro, which may explain why monotherapy with these agents frequently fails to eradicate biofilm infections. In fact, biofilms were resistant to antibiotics at concentrations 10-1000 times greater than the ones required to kill free-living or planktonic cells. The only antibiotics able to inhibit biofilm eradication on 50 % of isolates were ceftaroline and gentamicin. CONCLUSIONS: The results suggest that the antibiotic susceptibility patterns cannot be applied to biofilm established infections. Selection of antimicrobial therapy is a critical step in DFI and should aim at overcoming biofilm disease in order to optimize the outcomes of this complex pathology.BioMed CentralRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEMottola, CMatias, CMendes, JJMelo-Cristino, JTavares, LCavaco-Silva, POliveira, M2016-11-10T16:07:24Z2016-06-232016-06-23T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2579engBMC Microbiol. 2016 Jun 23;16(1):11910.1186/s12866-016-0737-0info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:38:28Zoai:repositorio.chlc.min-saude.pt:10400.17/2579Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:19:55.657157Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
title Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
spellingShingle Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
Mottola, C
HSM MED
Anti-Bacterial Agents/pharmacology
Biofilms/drug effects
Biofilms/growth & development
Cephalosporins/pharmacology
Diabetic Foot/drug therapy
Diabetic Foot/microbiology
Gentamicins/pharmacology
Methicillin-Resistant Staphylococcus aureus/drug effects
Methicillin-Resistant Staphylococcus aureus/genetics
Methicillin-Resistant Staphylococcus aureus/physiology
Microbial Sensitivity Tests
Polymerase Chain Reaction/methods
Staphylococcal Infections/drug therapy
Staphylococcal Infections/microbiology
Staphylococcus aureus/drug effects
Staphylococcus aureus/genetics
Staphylococcus aureus/isolation & purification
Staphylococcus aureus/physiology
beta-Lactams/pharmacology
title_short Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
title_full Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
title_fullStr Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
title_full_unstemmed Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
title_sort Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections
author Mottola, C
author_facet Mottola, C
Matias, C
Mendes, JJ
Melo-Cristino, J
Tavares, L
Cavaco-Silva, P
Oliveira, M
author_role author
author2 Matias, C
Mendes, JJ
Melo-Cristino, J
Tavares, L
Cavaco-Silva, P
Oliveira, M
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Mottola, C
Matias, C
Mendes, JJ
Melo-Cristino, J
Tavares, L
Cavaco-Silva, P
Oliveira, M
dc.subject.por.fl_str_mv HSM MED
Anti-Bacterial Agents/pharmacology
Biofilms/drug effects
Biofilms/growth & development
Cephalosporins/pharmacology
Diabetic Foot/drug therapy
Diabetic Foot/microbiology
Gentamicins/pharmacology
Methicillin-Resistant Staphylococcus aureus/drug effects
Methicillin-Resistant Staphylococcus aureus/genetics
Methicillin-Resistant Staphylococcus aureus/physiology
Microbial Sensitivity Tests
Polymerase Chain Reaction/methods
Staphylococcal Infections/drug therapy
Staphylococcal Infections/microbiology
Staphylococcus aureus/drug effects
Staphylococcus aureus/genetics
Staphylococcus aureus/isolation & purification
Staphylococcus aureus/physiology
beta-Lactams/pharmacology
topic HSM MED
Anti-Bacterial Agents/pharmacology
Biofilms/drug effects
Biofilms/growth & development
Cephalosporins/pharmacology
Diabetic Foot/drug therapy
Diabetic Foot/microbiology
Gentamicins/pharmacology
Methicillin-Resistant Staphylococcus aureus/drug effects
Methicillin-Resistant Staphylococcus aureus/genetics
Methicillin-Resistant Staphylococcus aureus/physiology
Microbial Sensitivity Tests
Polymerase Chain Reaction/methods
Staphylococcal Infections/drug therapy
Staphylococcal Infections/microbiology
Staphylococcus aureus/drug effects
Staphylococcus aureus/genetics
Staphylococcus aureus/isolation & purification
Staphylococcus aureus/physiology
beta-Lactams/pharmacology
description BACKGROUND: Foot infections are a major cause of morbidity in people with diabetes and the most common cause of diabetes-related hospitalization and lower extremity amputation. Staphylococcus aureus is by far the most frequent species isolated from these infections. In particular, methicillin-resistant S. aureus (MRSA) has emerged as a major clinical and epidemiological problem in hospitals. MRSA strains have the ability to be resistant to most β-lactam antibiotics, but also to a wide range of other antimicrobials, making infections difficult to manage and very costly to treat. To date, there are two fifth-generation cephalosporins generally efficacious against MRSA, ceftaroline and ceftobripole, sharing a similar spectrum. Biofilm formation is one of the most important virulence traits of S. aureus. Biofilm growth plays an important role during infection by providing defence against several antagonistic mechanisms. In this study, we analysed the antimicrobial susceptibility patterns of biofilm-producing S. aureus strains isolated from diabetic foot infections. The antibiotic minimum inhibitory concentration (MIC) was determined for ten antimicrobial compounds, along with the minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC), followed by PCR identification of genetic determinants of biofilm production and antimicrobial resistance. RESULTS: Results demonstrate that very high concentrations of the most used antibiotics in treating diabetic foot infections (DFI) are required to inhibit S. aureus biofilms in vitro, which may explain why monotherapy with these agents frequently fails to eradicate biofilm infections. In fact, biofilms were resistant to antibiotics at concentrations 10-1000 times greater than the ones required to kill free-living or planktonic cells. The only antibiotics able to inhibit biofilm eradication on 50 % of isolates were ceftaroline and gentamicin. CONCLUSIONS: The results suggest that the antibiotic susceptibility patterns cannot be applied to biofilm established infections. Selection of antimicrobial therapy is a critical step in DFI and should aim at overcoming biofilm disease in order to optimize the outcomes of this complex pathology.
publishDate 2016
dc.date.none.fl_str_mv 2016-11-10T16:07:24Z
2016-06-23
2016-06-23T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/2579
url http://hdl.handle.net/10400.17/2579
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv BMC Microbiol. 2016 Jun 23;16(1):119
10.1186/s12866-016-0737-0
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131296101826560